{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"42"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"42"}],"units":"Participants"}],"description":"For patients going on to stem cell collection, the total number of CD34 positive cells collected per collection, days to platelets over 20,000 without transfusion and ANC over 1000 will be recorded. If a patient fails to collect adequate stem cells for transplant, this will be recorded as such. The number of patients with successful stem cell mobilization are reported.","groups":[{"description":"Patients receive carfilzomib IV on days 1, 2, 8, 9, 15, and 16; oral cyclophosphamide on days 1, 8, and 15; oral dexamethasone on days 1, 8, 15, and 22; and oral thalidomide on days 1-28.","id":"OG000","title":"All Treated Patients"}],"paramType":"NUMBER","populationDescription":"Of the 64 patients that began protocol treatment, stem cell harvesting was attempted on 42 patients.","reportingStatus":"POSTED","timeFrame":"Following the first 4 courses of treatment","title":"Stem Cell Collection and Engraftment (Phase II)","type":"SECONDARY","unitOfMeasure":"participants"}